These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33917853)

  • 1. Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods.
    Gindele R; Pénzes-Daku K; Balogh G; Kállai J; Bogáti R; Bécsi B; Erdődi F; Katona É; Bereczky Z
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33917853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and Origin of the Founder Antithrombin Budapest 3 (p.Leu131Phe) Mutation; Its High Prevalence in the Roma Population and Its Association With Cardiovascular Diseases.
    Bereczky Z; Gindele R; Fiatal S; Speker M; Miklós T; Balogh L; Mezei Z; Szabó Z; Ádány R
    Front Cardiovasc Med; 2020; 7():617711. PubMed ID: 33614741
    [No Abstract]   [Full Text] [Related]  

  • 3. Heparin binding affinity of normal and genetically modified antithrombin III measured using a monoclonal antibody to the heparin binding site of antithrombin III.
    Watton J; Longstaff C; Lane DA; Barrowcliffe TW
    Biochemistry; 1993 Jul; 32(28):7286-93. PubMed ID: 8343518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary: phenotype analysis in a large cohort.
    Gindele R; Oláh Z; Ilonczai P; Speker M; Udvari Á; Selmeczi A; Pfliegler G; Marján E; Kovács B; Boda Z; Muszbek L; Bereczky Z
    J Thromb Haemost; 2016 Apr; 14(4):704-15. PubMed ID: 26748602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and laboratory characteristics of antithrombin deficiencies: A large cohort study from a single diagnostic center.
    Gindele R; Selmeczi A; Oláh Z; Ilonczai P; Pfliegler G; Marján E; Nemes L; Nagy Á; Losonczy H; Mitic G; Kovac M; Balogh G; Komáromi I; Schlammadinger Á; Rázsó K; Boda Z; Muszbek L; Bereczky Z
    Thromb Res; 2017 Dec; 160():119-128. PubMed ID: 29153735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism.
    Martínez-Martínez I; Navarro-Fernández J; Østergaard A; Gutiérrez-Gallego R; Padilla J; Bohdan N; Miñano A; Pascual C; Martínez C; de la Morena-Barrio ME; Aguila S; Pedersen S; Kristensen SR; Vicente V; Corral J
    Blood; 2012 Jul; 120(4):900-4. PubMed ID: 22498748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity.
    Olson ST; Frances-Chmura AM; Swanson R; Björk I; Zettlmeissl G
    Arch Biochem Biophys; 1997 May; 341(2):212-21. PubMed ID: 9169007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D.
    Dementiev A; Swanson R; Roth R; Isetti G; Izaguirre G; Olson ST; Gettins PGW
    J Biol Chem; 2013 Nov; 288(47):33611-33619. PubMed ID: 24068708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.
    Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K
    Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin heparin binding site deficiency: A challenging diagnosis of a not so benign thrombophilia.
    Orlando C; Heylen O; Lissens W; Jochmans K
    Thromb Res; 2015 Jun; 135(6):1179-85. PubMed ID: 25837307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and functional characterization of two natural heparin-binding site variants of antithrombin.
    Dinarvand P; Yang L; Villoutreix BO; Rezaie AR
    J Thromb Haemost; 2018 Feb; 16(2):330-341. PubMed ID: 29215785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with intrauterine fetal demise.
    Bauters A; Zawadzki C; Bura A; Théry C; Watel A; Subtil D; Aiach M; Emmerich J; Jude B
    Blood Coagul Fibrinolysis; 1996 Oct; 7(7):705-10. PubMed ID: 8958394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation.
    Martínez-Martínez I; Ordóñez A; Navarro-Fernández J; Pérez-Lara A; Gutiérrez-Gallego R; Giraldo R; Martínez C; Llop E; Vicente V; Corral J
    Haematologica; 2010 Aug; 95(8):1358-65. PubMed ID: 20435622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residues Tyr253 and Glu255 in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa.
    Izaguirre G; Olson ST
    J Biol Chem; 2006 May; 281(19):13424-13432. PubMed ID: 16517611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.
    Ersdal-Badju E; Lu A; Peng X; Picard V; Zendehrouh P; Turk B; Björk I; Olson ST; Bock SC
    Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):323-30. PubMed ID: 7646463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity.
    Picard V; Ersdal-Badju E; Bock SC
    Biochemistry; 1995 Jul; 34(26):8433-40. PubMed ID: 7599134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure.
    Fan B; Crews BC; Turko IV; Choay J; Zettlmeissl G; Gettins P
    J Biol Chem; 1993 Aug; 268(23):17588-96. PubMed ID: 8349638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.